European Medicines Agency Adopts Positive Opinion for Merck’s KEYTRUDA® (pembrolizumab) for Six-Week Dosing Schedule Across All Current Monotherapy Indications
Go back to European Medicines Agency Adopts Positive Opinion for Merck’s KEYTRUDA® (pembrolizumab) for Six-Week Dosing Schedule Across All Current Monotherapy Indications| Merck & Co. (NYSE: MRK) | Delayed: 124.03 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $124.03 | 52 Week High | $65.46 | |||
| Open | $124.03 | 52 Week Low | $47.97 | |||
| Day High | $124.03 | P/E | 84.37 | |||
| Day Low | $124.03 | EPS | $1.47 | |||
| Volume | 515 | |||||
